SHANGHAI, CHINA, July, 16, 2021 –STA Pharmaceutical Co., Ltd., a WuXi AppTec Company (WuXi STA)–and InnoCare Pharma Limited (HKEX: 09969), announced the signing of a strategic partnership agreement.
InnoCare Pharma is a commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. Currently InnoCare has developed a pipeline with over 10 innovative drugs in the field of cancer and autoimmune diseases, including one commercial-stage, five clinical-stage and several preclinical-stage drug candidates. In 2020, InnoCare’s BTK inhibitor orelabrutinib was approved for two indications in China. As InnoCare’s Contract Development and Manufacturing Organization (CDMO) partner, WuXi STA has supported the development and commercialization of orelabrutinib, providing API, amorphous solid dispersion, tablet manufacturing and packaging for this innovative drug. The signing of this strategic partnership agreement will enhance the partnership between the two companies.
Under the terms of this agreement, WuXi STA will become the preferred CDMO partner for InnoCare’s current and future pipeline projects of small molecule, oligonucleotide, peptide and complex chemical conjugate, including but not limited to the API process development, manufacturing, analytical and regulatory filing support.
As a premier CDMO, WuXi STA established an industry leading integrated CMC platform with eight R&D and manufacturing sites globally, as well as a quality and EHS system meeting global standard. Under the strategic partnership agreement, WuXi STA will support InnoCare to accelerate the development of their pipeline drugs.
Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare, said, “We are very happy to enhance our partnership with WuXi STA, who has been our trusted partner for a long time. The collaboration between the two companies on the orelabrutinib project was very successful. InnoCare is committed to our core value of ‘Science Drives Innovation’, and has built up a strong new drug pipeline for the treatment of cancer and autoimmune diseases. We are dedicated to accelerating market entrance of our new drugs for the benefit of global patients.”
Dr. Minzhang Chen, CEO of WuXi STA, commented: “We are delighted to expand our partnership with InnoCare, which is another great example of how WuXi STA empowers our partners and earns their trust to support more projects in their pipeline. We are looking forward to leveraging our industry-leading capabilities and expertise, along with our well-established global standard quality system, to help accelerate the development and commercialization of InnoCare’s pipeline drugs to benefit patients around the world.”
About InnoCare Pharma
InnoCare Pharma (HKEX:09969) is a commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare was founded in 2015 by Dr. Jasmine Cui, who has extensive experience in new drug development and business management and the world-renowned structural biologist Dr. Yigong Shi. InnoCare has branches in Beijing, Nanjing, Guangzhou, Shanghai, New Jersey and Boston.
InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline targeting liquid tumors, solid tumors, and autoimmune diseases. On March 23, 2020, InnoCare was successfully listed on Hong Kong Stock Exchange.
About WuXi STA
WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier contract development and manufacturing organization (CDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate. For more information, please visit: https://sta.wuxiapptec.com/
